Akeso's AK150 Enters Clinical Trials, Shares Tick Higher
Akeso announced IND clearance from China’s National Medical Products Administration for AK150, a trispecific antibody designed to target ILT2, ILT4, and CSF1R concurrently. The clearance allows clinical testing in patients with advanced solid tumors and prompted a roughly 6% rise in the company's Hong Kong-listed shares to HK$117 as of 05:29 GMT.